Healthcare Disparities in Hidradenitis Suppurativa in the US: TARGET-DERM HS

HS disproportionately affects socioeconomically disadvantaged populations and racial/ethnic minorities, but real-world data characterizing health disparities in HS disease severity, insurance coverage, and biologic utilization across racial groups in a large US/Canadian registry were limited.

The TARGET-DERM HS registry was analyzed to compare Hurley staging, comorbidity burden, insurance type, and biologic treatment rates across Non-Hispanic Black, Non-Hispanic White, Hispanic, and other/not-reported patient groups in a cohort of 697 enrolled US HS patients.

Documenting that Non-Hispanic Black patients have higher HS disease severity and the lowest private insurance rates—yet the highest biologic utilization—provides a nuanced real-world disparity profile that supports health equity advocacy, diverse enrollment planning, and the design of access programs for HS advanced therapies.

HS health disparity characterization for equity-aligned clinical program and access strategy design, Real-world racial and ethnic disparity evidence in HS disease severity and biologic utilization, Disparity data supporting diverse enrollment mandates and health equity commitments for HS drug development